Dr. Muro on Results of PaFF-K Study in Colorectal Cancer

Kei Muro, MD
Published: Monday, Jan 23, 2017



Kei Muro, MD, Aichi Cancer Center Hospital, discusses the results of the PaFF-K study in metastatic colorectal cancer (mCRC).

This phase II multicenter study investigated the efficacy and safety of panitumumab (Vectibix) with FOLFOX or FOLFIRI as a first-line chemotherapy for KRAS-wild type mCRC. Of 162 total patients, 140 were treated with FOLFOX plus panitumumab and 22 with FOLFIRI plus panitumumab.

The overall response rate was 51.2% (95% CI: 43.3-59.2) and the disease control rate was 82.1% (95%CI:75.3-87.7) with a median follow-up of 28.2 months. Median progression-free survival and overall survival was 9.2 months for the FOLFOX arm and 33.8 months for the FOLFIRI arm. Maximum tumor shrinkage was observed at 10 and 16 weeks, respectively, in 115 patients.
 


Kei Muro, MD, Aichi Cancer Center Hospital, discusses the results of the PaFF-K study in metastatic colorectal cancer (mCRC).

This phase II multicenter study investigated the efficacy and safety of panitumumab (Vectibix) with FOLFOX or FOLFIRI as a first-line chemotherapy for KRAS-wild type mCRC. Of 162 total patients, 140 were treated with FOLFOX plus panitumumab and 22 with FOLFIRI plus panitumumab.

The overall response rate was 51.2% (95% CI: 43.3-59.2) and the disease control rate was 82.1% (95%CI:75.3-87.7) with a median follow-up of 28.2 months. Median progression-free survival and overall survival was 9.2 months for the FOLFOX arm and 33.8 months for the FOLFIRI arm. Maximum tumor shrinkage was observed at 10 and 16 weeks, respectively, in 115 patients.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x